Arca
Skip to content
Tools
Tools

ADA: Adenosine deaminase

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Catalyzes the hydrolytic deamination of adenosine and 2- deoxyadenosine.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who Is On It, and How Far Along

Every drug ChEMBL records acting on ADA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved1

  • Pentostatin

Phase 30

    Phase 21

    • Coformycin

    Phase 10

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      PentostatinApprovedPfizerSmall moleculeInhibitorAdenosine deaminase inhibitor10Boxed warning
      CoformycinPhase 2IncyteSmall moleculeInhibitorAdenosine deaminase inhibitor7—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.
      A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic TherapyPentostatin, CoformycinPhase 3Active, not recruitingIncyte Corporation2025-02-12
      A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic AnemiaPentostatin, CoformycinPhase 1RecruitingCity of Hope Medical Center2023-03-07
      Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...PentostatinPhase 1 / Phase 2RecruitingNational Cancer Institute (NCI)2022-07-22
      Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell LymphomaPentostatinPhase 2Active, not recruitingNational Cancer Institute (NCI)2019-04-22
      Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or DysregulationPentostatin, CoformycinPhase 2Active, not recruitingNational Cancer Institute (NCI)2018-09-10
      A Blood Stem Cell Transplant for Sickle Cell DiseasePentostatin, CoformycinPhase 1Active, not recruitingCity of Hope Medical Center2017-08-15
      Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell DiseasePentostatin, CoformycinPhase 1 / Phase 2Active, not recruitingNational Heart, Lung, and Blood Institute (NHLBI)2017-03-13
      Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary ImmunodeficienciesPentostatinPhase 2RecruitingNational Cancer Institute (NCI)2015-10-20
      Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant FailureCoformycinPhase 2Active, not recruitingNational Heart, Lung, and Blood Institute (NHLBI)2014-04-07
      Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaCoformycinPhase 2Active, not recruitingNational Cancer Institute (NCI)2010-02-01

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency
      0.86
      Partial adenosine deaminase deficiency
      0.64
      Omenn syndrome
      0.47
      T-B+ severe combined immunodeficiency
      0.46
      T-B- severe combined immunodeficiency
      0.46
      Neoplasm
      0.40
      Type 2 diabetes mellitus
      0.39
      Anemia
      0.37
      Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive
      0.34

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1910, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P00813, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.